Immunological and Clinical Features of Prolonged Omicron SARS-CoV-2 in Hematologic Patients
Overview
This study analyzed 160 hematologic disorder patients with breakthrough Omicron COVID-19 infections, identifying 36.9% with prolonged viral shedding (PVS). PVS was associated with significant depletion of CD4+ and CD19+ cells, increased exhausted CD4+ T-cells, and poor neutralizing antibody responses against Omicron subvariants, especially in those treated with bendamustine plus anti-CD20 antibodies.
Background
Prolonged viral shedding (PVS) of SARS-CoV-2, indicating failure to clear the virus, has been predominantly reported in patients with hematologic diseases, raising concerns about outcomes and transmission. Prior to Omicron, PVS was linked to combined B-cell and CD4+ T-cell depletion. However, the immunological and clinical characteristics of PVS during the Omicron era remain poorly understood. This study aimed to identify risk factors and immune profiles associated with Omicron PVS in a hematologic disorder cohort.
Data Highlights
Parameter
PVS Patients (n=17)
Non-PVS Patients (n=29)
P Value
CD4+ T-cell count (cells/μL)
174 (IQR 75–290)
409 (IQR 216–555)
0.001
CD19+ B-cell count (cells/μL)
0 (IQR 0–9)
37 (IQR 0–157)
0.004
Exhausted CD4+ T-cells (%)
40.7
11.4
0.019
Neutralizing antibody positivity against BA.1 (%)
14.2
66.7
0.002
Neutralizing antibody positivity against BA.2 (%)
14.2
70.4
<0.001
Neutralizing antibody positivity against BA.5 (%)
7.1
62.9
<0.001
Key Findings
Prolonged viral shedding (≥21 days with Ct <30) occurred in 36.9% of analyzed hematologic patients with Omicron infection.
Patients with PVS had significant depletion of CD4+ T-cells and CD19+ B-cells compared to non-PVS patients.
Exhausted CD4+ T-cells (PD-1 high) were significantly increased in PVS patients, indicating T-cell dysfunction.
Neutralizing antibody responses against Omicron subvariants BA.1, BA.2, and BA.5 were markedly reduced in PVS patients.
Recent treatment with bendamustine plus anti-CD20 antibodies was strongly associated with PVS and poor viral clearance.
Despite antiviral therapies, some patients exhibited viral persistence beyond 42 days, with the longest duration recorded at 85 days.
Clinical Implications
Clinicians should recognize that hematologic patients, especially those recently treated with bendamustine and anti-CD20 antibodies, are at high risk for prolonged Omicron viral shedding and impaired immune responses. Monitoring of viral load and immune cell subsets may guide management. Enhanced antiviral strategies and close follow-up are warranted to mitigate severe outcomes and transmission risk in this vulnerable population.
Conclusion
Prolonged SARS-CoV-2 Omicron infection in hematologic disorder patients is characterized by combined B-cell and CD4+ T-cell depletion, T-cell exhaustion, and impaired neutralizing antibody responses, particularly following bendamustine plus anti-CD20 therapy. These findings highlight the need for tailored clinical management to improve viral clearance and patient outcomes.
References
Lee et al. 2022 -- Prolonged viral shedding in hematologic disease patients
Current Study 2023 -- Immunological and Clinical Features of Extended SARS-CoV-2 Omicron Infections in Patients with Hematologic Disorders
The Temple Lung Center conducts one of the most comprehensive lung disease clinical trials programs in the country. Our advancements in basic, translational and clinical research are changing lung disease treatment. By pioneering effective therapies, we bring hope to patients with serious and debilitating lung diseases.
